The drug selection process in our International Linked Clinical Trials (iLCT) programme is governed and evaluated by a committee of world leading scientists, physicians and advocates, all experts in their field of Parkinson’s research.

The iLCT Committee

Learn More

Patrik Brundin, M.D., Ph.D. (Scientific Committee chair)

Learn More

Professor Roger Barker

Learn More

Flint Beal, M.D.

Learn More

Dr Camille Carroll

Learn More

Mark R. Cookson, Ph.D.

Learn More

Ted Dawson, M.D., Ph.D.

Learn More

David Devos, Ph.D.

Learn More

Tim Greenamyre, M.D., Ph.D.

Learn More

Howard Federoff, M.D., Ph.D.

Learn More

Brian Fiske, Ph.D.

Learn More

Tom Folytnie, Ph.D.

Learn More

Karl Kieburtz, M.D., MPH

Learn More

Dimitri Krainc, M.D.

Learn More

Andrew Lees, F.R.C.P., FMedSci

Learn More

Mark Mattson, Ph.D.

Learn More

Michael Schwarzschild, M.D., Ph.D.

Learn More

David Simon, M.D.

Learn More

David Sulzer, M.D.

Learn More

Caroline Tanner, M.D., Ph.D., F.A.A.N.

Learn More

John Trojanowski, M.D.

Learn More

Director of Research and Development
Dr Richard Wyse

Learn More

Deputy Director of Research
Dr Simon Stott